Related Experiment Video
Updated: Sep 25, 2025
Spectral Karyotyping to Study Chromosome Abnormalities in Humans and Mice with Polycystic Kidney Disease
Published on: February 3, 2012
CDKL5 deficiency disorder: clinical features, diagnosis, and management
Helen Leonard1, Jenny Downs2, Tim A Benke3
1Telethon Kids Institute, The University of Western Australia, Perth, WA, Australia.
Insights
CDKL5 deficiency disorder (CDD) is a severe neurodevelopmental condition causing early-onset, drug-resistant seizures and impaired development. While treatments are limited, new therapeutic trials offer hope for patients with this rare genetic disorder.
Area of Science:
- Neurology
- Genetics
- Pediatrics
Background:
- CDKL5 deficiency disorder (CDD) is a rare genetic disorder classified as a developmental epileptic encephalopathy.
- It presents with early-onset, refractory seizures and severe developmental impairments, distinct from Rett syndrome.
Purpose of the Study:
- To provide an overview of CDKL5 deficiency disorder, including its characteristics, clinical variability, and current management challenges.
- To highlight the need for clinician familiarity with CDD complexities for accurate diagnosis and family counseling.
Main Methods:
- Literature review and synthesis of existing knowledge on CDKL5 deficiency disorder.
- Analysis of clinical presentation, genetic basis, and treatment outcomes.
Main Results:
- CDD is characterized by early-onset, refractory seizures and significant developmental delays, affecting motor skills and other milestones.
- Gastrointestinal, sleep, and musculoskeletal issues are common, with a notably higher prevalence of cerebral visual impairment in CDD.
- Clinical variability exists, likely influenced by genetic factors.
Conclusions:
- CDD requires specialized clinical understanding for effective diagnosis and family support.
- Conventional antiseizure medications show limited efficacy, but emerging treatments and ongoing trials offer potential therapeutic avenues.
Abstract:
CDKL5 deficiency disorder (CDD) was first identified as a cause of human disease in 2004. Although initially considered a variant of Rett syndrome, CDD is now recognised as an independent disorder and classified as a developmental epileptic encephalopathy. It is characterised by early-onset (generally within the first 2 months of life) seizures that are usually refractory to polypharmacy. Development is severely impaired in patients with CDD, with only a quarter of girls and a smaller proportion of boys achieving independent walking; however, there is clinical variability, which is probably genetically determined. Gastrointestinal, sleep, and musculoskeletal problems are common in CDD, as in other developmental epileptic encephalopathies, but the prevalence of cerebral visual impairment appears higher in CDD. Clinicians diagnosing infants with CDD need to be familiar with the complexities of this disorder to provide appropriate counselling to the patients' families. Despite some benefit from ketogenic diets and vagal nerve stimulation, there has been little evidence that conventional antiseizure medications or their combinations are helpful in CDD, but further treatment trials are finally underway.
Related Concept Videos
02:34Inhibition of Cdk Activity
02:15M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
01:24Chronic Kidney Disease II: Clinical Manifestations
01:20Inborn Errors of Metabolism
02:39Positive Regulator Molecules
01:28Chronic Kidney Disease III: Interprofessional Care